Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 5:00 AM
Ignite Modification Date:
2025-12-25 @ 5:00 AM
NCT ID:
NCT06918418
Brief Summary:
The goal of this clinical trial was to determine if adding ipratropium bromide to salbutamol improves asthma treatment in children.
The main question this study aimed to answer was:
Does combining ipratropium with salbutamol improve asthma symptoms more effectively than salbutamol alone?
Researchers compared salbutamol alone to a combination of salbutamol and ipratropium in children with acute asthma.
Participants:
(i) Received either salbutamol alone or salbutamol with ipratropium via nebulization for 4 hours
(ii) Had their asthma symptoms assessed before and after treatment
(iii) Were discharged with continued treatment and counseling if stable
This study was conducted in the Department of Pediatric Medicine, Children's Hospital Multan, over six months. A total of 60 children with acute asthma were included.
Detailed Description:
Children presenting with asthma exacerbation were assessed for eligibility. Eligible participants had their baseline characteristics recorded including age, gender, history of parental asthma, duration of asthma diagnosis, use of asthma controllers (inhaled corticosteroids, Long Acting Beta Agonist (LABA), Montelukast) \& baseline pulmonary asthma score. Through lottery method using sequentially numbered sealed opaque envelopes children were assigned to group A and group B treatments. At the end of 4-hours of therapy, pulmonary asthma score was re-assessed by pediatrician not aware of treatment assigned. Once stabilized, the children were discharged on regular nebulization therapy with controller medication after proper counseling.
Study:
NCT06918418
Study Brief:
Protocol Section:
NCT06918418